Recent exposure of what the company is bringing to the table has clearly lit a fire under the stock price. A typical technical pull-back has presented us with an opportune time to take a much closer look at the company for consideration as a portfolio addition, particularly with multiple expanding catalysts as both a pure biotechnology play and eventual industry leader in the ever-popular medical marijuana and cutting-edge living cell encapsulation industry.
Market Data 
Markets 
AI
